Cat. No. 1692
Chemical Name: 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl
Biological ActivityPotent phosphodiesterase III A (PDE3A) inhibitor (IC50 = 0.2 μM) and inhibitor of adenosine uptake. Has antimitogenic, antithrombotic, vasodilatory and cardiotonic properties in vivo. Also affects lipid levels in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Schror (2002) The pharmacology of cilostazol. Diabetes Obes.Metab. 4 S14. PMID: 12180353.
Shintani et al (1985) General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: effects on the central nervous system. Arzneimittelforschung 35 1157. PMID: 4074429.
Shintani et al (1985) General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: effects on the peripheral organs. Arzneimittelforschung 35 1163. PMID: 3000392.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Cilostazol from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Cilostazol, supplier, PDE3A, inhibitors, inhibits, adenosines, reuptake, Phosphodiesterases, ENT1, Purine, Transporters, Pyrimidine, Equilibrative, Nucleoside, Monoamine, Neurotransmitter, Tocris Bioscience, Phosphodiesterase Inhibitor products
Find multiple products by catalog number
New Products in this Area
CYP17 inhibitor; also androgen receptor antagonistPF 04449613
Potent PDE9 inhibitor; brain penetrantEggmanone
Potent and selective PDE4 inhibitor; suppresses hedgehog signaling
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.